Histopathological and biochemical studies on immunocompetent and immunocompromised Hymenolepis nana infected mice treated with Commiphora molmol (Mirazid).

Hymenolepiasis is a common parasitic infection of children and considered an opportunistic disease with a life-threatening effect among immunocompromised patients through cysticercoid dissemination. Mirazid (Commiphora molmol) is new phytotherapy for hymenolepiasis. So, the present study aimed to evaluate the effects of Mirazid treatment comparing to Praziquantel (PZQ) (standard treatment) among immunocompetent and immunocompromised infected albino mice through biochemical and histopathological parameters. A total of 60 clean male albino mice (immunocompetent group) were divided into equal five groups which were infected and treated with Mirazid beside PZQ. Another 72 infected immunocompromised animals were divided into equal six groups and were also treated with Mirazid and PZQ. Liver and kidney functions were estimated as well as histopathological examination of intestine and liver. Levels of AST in the serum of infected mice treated with Mirazid or PZQ recorded a highly significant increase compared to the normal control group. The percentage of increase was 83.30% and 36.60% respectively. While the infected group recorded a non-significant decrease in AST level and the percentage of decrease was - 7.4%. Immunocompetent groups showed a positive significant correlation with the control Mirazid or control PZQ groups recorded an increase in liver function enzymes (AST, Bilirubin, and GGT) (P < 0.001) comparing to the normal control group. In conclusion, Mirazid showed higher cure rates than PZQ, 95.45%, and 74.54% on the 15th and the 21st days, it reached 100% respectively associated with good improvement of histopathological changes in intestine and liver.

An investigation into the impact of enteric coated of aspirin in patients with newly diagnosed ischemic stroke (ECASIS).

INTRODUCTION: Uncertainty remains regarding the impact of enteric-coated (EC) aspirin as it relates to the reduction of cardiovascular risk. We hypothesize that EC formulation based on a previous report may blunt aspirin response as evidenced by reduced Thromboxane A2 (TXA 2) levels in diabetic patients. Thus, it was imperative to ascertain and validate the effect of the EC formulation of Aspirin on the Thromboxane B2 (TXB2) level. METHODS/DESIGN: An open-label consecutive randomized interventional controlled trial. Patients with newly diagnosed ischemic stroke who are just about to start Aspirin were assessed for eligibility and inclusion in our trial. Consecutive patients (admitted to the stroke unit of Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar) will be randomized to receive either EC aspirin or plain Aspirin. They will be required to continue taking them throughout the study (3 days). Demographics and laboratory records of the study participants will be abstracted from online records. Further study variables will be obtained manually in designated case record forms (CRF). The primary outcomes are the incidence of aspirin non-responders (level of residual serum TXB2 associated with elevated thrombotic risk (<99.0% inhibition or TXB2 >3.1 ng/mL) within 72 h after three daily aspirin doses). Whereas secondary outcomes are the incidence of GIT bleeding of various preparations of Aspirin. The study was approved by MRC and IRB of Hamad Medical Corporation (MRC number: 01-18-156). DISCUSSION: This trial will determine potential differences in the efficacy of EC Aspirin and plain Aspirin on the Thromboxane B2 level. Additionally, it will ascertain the tolerability and safety of both formulations of Aspirin in patients with newly diagnosed ischemic stroke. These results will either support the current notion of no difference between the two formulations. However, if a difference is found, this will invite for future trials exploring clinical outcomes occurrence between various formulations. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov NCT04330872 registered on April 2, 2020.